0N4A.L
OASMIA PHARMACEUTICAL AB OASMIA
£0.09
+4.71%
2026-02-12
About OASMIA PHARMACEUTICAL AB OASMIA
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was founded in 1988 and is headquartered in Solna, Sweden.
Key Fundamentals
EPS (TTM)
£-0.26
ROE
-24.1%
Profit Margin
0.0%
Debt/Equity
10.44
Price/Book
0.00
Beta
0.83
Market Cap
£13.1M
Avg Volume (10D)
3K
Recent Breakout Signals
No recent breakout signals detected for 0N4A.L.
Recent Price Range (60 Days)
60D High
£0.49
60D Low
£0.08
Avg Volume
9K
Latest Close
£0.09
Get breakout alerts for 0N4A.L
Sign up for Breakout Scanner to receive daily notifications when 0N4A.L triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
OASMIA PHARMACEUTICAL AB OASMIA (0N4A.L) is listed on the London Stock Exchange (LSE). Breakout Scanner monitors 0N4A.L daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups.. Data is provided for informational purposes only and does not constitute financial advice.